The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.
about
HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loadsThe Antibody Response against HIV-1Mother-infant HIV transmission: do maternal HIV-specific antibodies protect the infant?Early development of broadly neutralizing antibodies in HIV-1-infected infantsEvidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.HIV-1 autologous antibody neutralization associates with mother to child transmissionThe genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodiesPassively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality.Antibodies for prevention of mother-to-child transmission of HIV-1Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth.Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection.Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variantsEvidence for efficient vertical transfer of maternal HIV-1 envelope-specific neutralizing antibodies but no association of such antibodies with reduced infant infectionTransient compartmentalization of simian immunodeficiency virus variants in the breast milk of african green monkeysImmunotherapies to prevent mother-to-child transmission of HIVThe role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures.Neutralizing antibodies and control of HIV: moves and countermoves.Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission RiskMaternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.Human immunodeficiency virus type 1 mother-to-child transmission and prevention: successes and controversies.Role of maternal, transplacentally acquired HIV-1-specific neutralizing antibodies in protecting the uninfected offspring against HIV-1 transmission via breast milkBroadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
P2860
Q21131399-8AB41F8D-018F-4AF4-90D3-41780D69B635Q27000889-2A59D229-F608-4FAE-A731-F5DB38668246Q27008774-9602CFD1-3E75-43E9-A323-1374F08AABA9Q33764917-BA6C6A22-F177-4104-B0B4-1F73EEA96720Q34819651-813E611C-3613-432D-9DA2-4D6BB42B7C30Q34853667-F5441447-2554-438B-8E83-97CB91567CDAQ35140408-83033C2A-DE53-4560-A165-0FF44E034E47Q35192641-84CC421A-AE79-4DB4-9667-221101C69CDDQ35352866-7E536719-7AB0-41E7-A1BE-EE495305F249Q35619402-E23227FF-4273-48E4-AB43-9391DA977431Q35867981-B0F1421B-C4F7-4F66-9CFE-650D7B83FE09Q36171833-55A1A24C-5362-4197-A44B-B4C5B8259259Q36184762-B9F77293-3D74-482B-A9E7-665B5F7A99EAQ36276632-55F27FE9-EC41-4800-99F9-E85E02E51FCFQ36334990-FE473818-52C9-4553-9A46-928CEF3BC3ACQ36588632-B5724FEB-B1C4-456E-AAF3-0975AD801424Q37247875-891F77E3-A46D-4BED-B088-AD2BB24AC443Q37252583-D25DB2FF-63CC-417A-B8EB-7ABB84F6C019Q37316629-C377E616-9D50-4158-86E4-AD99D8E2829BQ37365618-A9032DBD-A22D-47F4-AF1F-962202FEBFC3Q37607872-3048FC61-14DB-46AD-B296-5C720AEF903BQ37971867-CD54DCA1-191A-490C-8BF4-A1C2DB80DA96Q40331385-AB4A0A99-BDED-4A09-902C-B7D0EC42AA18Q42638889-8B89363F-F218-471A-95E7-850DD074EFD4Q45363198-1729CADD-D8E3-4EED-BBF0-C7747C47C92CQ56762893-E26925E6-37B7-4383-BC86-9CABA00D7B1CQ56974226-45DEBCF0-55A5-4043-A013-27554C8A9ACA
P2860
The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The breadth and potency of pas ...... the risk of infant infection.
@ast
The breadth and potency of pas ...... the risk of infant infection.
@en
The breadth and potency of pas ...... the risk of infant infection.
@nl
type
label
The breadth and potency of pas ...... the risk of infant infection.
@ast
The breadth and potency of pas ...... the risk of infant infection.
@en
The breadth and potency of pas ...... the risk of infant infection.
@nl
prefLabel
The breadth and potency of pas ...... the risk of infant infection.
@ast
The breadth and potency of pas ...... the risk of infant infection.
@en
The breadth and potency of pas ...... the risk of infant infection.
@nl
P2093
P2860
P50
P356
P1433
P1476
The breadth and potency of pas ...... the risk of infant infection.
@en
P2093
Catherine A Blish
Jennifer M Mabuka
John B Lynch
Zahra Jalalian-Lechak
P2860
P304
P356
10.1128/JVI.02216-10
P407
P577
2011-03-16T00:00:00Z